{"ATC Code":"QN06AX11","Abbreviation":[],"Absorption, Distribution and Excretion":"The absorption of this drug is rapid and complete. Due to first pass metabolism in the liver and metabolism in the gut wall, absolute bioavailability is about 50%. Peak blood concentrations are attained within about 2 hours after an oral dose. Food has little effect on the absorption of mirtazapine, and no dose adjustment is required if it is taken with food. Steady-state levels are achieved by about 5 days after the initial dose. Mirtazapine pharmacokinetics vary across gender and age range. Females and the elderly population have been shown to have higher blood concentrations in comparison to males and younger adults.","Adverse Effects":"Mirtazapine has several significant side effects. The adverse effects known to occur in \u003e10% of patients receiving this drug are listed below.","Aliases":["Mirtazapine","85650-52-8","Remeron","Mepirzepine","6-Azamianserin","Remergon","Zispin","Promyrtil","Remergil","Rexer","Avanza","Norset","Remeron SolTab","Mirtazapina","ORG 3770","Mirtazapinum","2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine","Org-3770","Mirataz","Mirtazapin","Mirtazapine anhydrous","Mepirzapine","Dtxsid0023325","1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine","A051Q2099Q","Org3770","Pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-","CHEBI:6950","Dtxcid503325","Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-","5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene","Remeronsoltab","6 Azamianserin","1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c]benzazepine","2-methyl-1,2,3,4,10,14b-hexahydropyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine","5-methyl-2,5,19-triazatetracyclo(13.4.0.0^(2,7).0^(8,13))nonadeca-1(19),8(13),9,11,15,17-hexaene","5-methyl-2,5,19-triazatetracyclo(13.4.0.02,7.08,13)nonadeca-1(15),8,10,12,16,18-hexaene","N06AX11","61337-67-5","Mirtazepine","Mepirzapin","Mirtazipine","Mfcd00865427","1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine","2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine","CHEMBL654","Org3770;(S)-6-Azamianserin","Ncgc00025346-02","Azamianserin","Smilon","2-methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene","Smr000466347","Sr-01000597530","Einecs 288-060-6","Mirtazapine CRS","Unii-a051q2099q","Org3770;(R)-6-Azamianserin","6-Aza-mianserin","1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c](2)benzazepine","1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;Mepirzepine;Org-3770","Reflex","(1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine","ME-2040","Schembl35408","Mls000759460","Mls001076676","Mls001424294","Mls006011449","orb322593","GTPL7241","orb1310902","Mirtazapine - Bio-X trade mark","Schembl29484433","HY-B0352R","Mirtazapine, \u003e=98%","Mirtazapine, 1mg/ml in Methanol","HMS2052H03","HMS2233K03","HMS3268F21","HMS3370B05","HMS3374J01","HMS3394H03","HMS3413C11","HMS3657M13","HMS3677C11","HMS3713P13","HMS3884O18","HMS5080H15","PS11 - Mirtazapine/Normirtazapine","HY-B0352","Mirtazapine 1.0 mg/ml in Methanol","MSK10500","Tox21_110965","Bdbm50115644","EBC-08263","Pdsp1_001529","Pdsp2_001513","s2016","STK711107","Akos005530681","CCG-101154","CCG-220556","DB00370","FM26014","KS-1086","NC00404","(14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine","Ncgc00025346-01","Ncgc00025346-08","AC-15480","BM164672","SY002095","Cas-61337-67-5","M2151","NS00009441","SW197784-4","En300-49851","C07570","D00563","Ab00698265_08","337M675","L001294","Q421930","Sr-01000597530-1","Sr-01000597530-4","Brd-a64977602-001-01-9","Brd-a64977602-001-04-3","Brd-a64977602-001-13-4","Brd-a64977602-001-14-2","Brd-a64977602-001-15-9","Z905065772","Mirtazapine, European Pharmacopoeia (EP) Reference Standard","Mirtazapine, United States Pharmacopeia (USP) Reference Standard","12-Methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene","2-Methyl-1,2,3,4,10,14b-hexahydrobenzo-[c]pyrazino[1,2-a]pyrido[3,2-f]azepine","Mirtazapine for system suitability, European Pharmacopoeia (EP) Reference Standard","5-methyl-2,5,19-triazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(15),8,10,12,16,18-hexaene","5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene","Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (.+/-.)-"],"Biological Half-Life":"20-40 hours","CAS":"85650-52-8","ChemicalClasses":["phenethylamine"],"Chirality":"racemic","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Antidepressive Agents","Antidepressive Agents, Second-Generation","Adrenergic alpha-2 Receptor Antagonists","Serotonin 5-HT2 Receptor Antagonists","Serotonin 5-HT3 Receptor Antagonists"],"Drug Indication":"This drug is indicated for the treatment of major depressive disorder and its associated symptoms.  Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.","EliminationHalfLife":"20 – 40 hours","Esters":[],"European Community (EC) Number":"288-060-6","Formating":[],"HMDB ID":"HMDB0014514","HeavyAtomCount":20,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Second-Generation; Adrenergic alpha-2 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT3 Receptor Antagonists","IUPACName":"5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene","InChI":"InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3","InChIKey":"RONZAEMNMFQXRA-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.","Mechanism of Action":"**Summary**  The mechanism of action of mirtazapine is not fully understood but may be explained by its effects on central adrenergic and serotonergic activity. This drug exhibits a fast onset of action, a high level of response, a manageable side-effect profile, and dual noradrenergic and serotonergic effects that are unique from the effects of other antidepressants.  **Effects on various receptors**  It has been shown that both noradrenergic and serotonergic activity increase following mirtazapine administration. The results of these studies demonstrate mirtazapine exerts antagonist activity at presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors in the central nervous system. This is thought to lead to enhanced noradrenergic and serotonergic activity, which are known to improve the symptoms of depression and form the basis of antidepressant therapy.  Mirtazapine is a strong antagonist of serotonin 5-HT2 and 5-HT3 receptors. It has not been found to bind significantly to the serotonin 5-HT1A and 5-HT1B receptors but indirectly increases 5-HT1A transmission.    In addition to the above effects, mirtazapine is a peripheral α1-adrenergic antagonist. This action may explain episodes of orthostatic hypotension that have been reported after mirtazapine use. Mirtazapine is a potent histamine (H1) receptor antagonist, which may contribute to its powerful sedating effects. The pain-relieving effects of mirtazapine may be explained by its effects on opioid receptors.","Melting Point":"114-116 °C","Metabolism/Metabolites":"Mirtazapine is heavily metabolized in humans. Demethylation and hydroxylation and subsequent glucuronide conjugation are the major pathways by which mirtazapine is metabolized. Data from in vitro studies on human liver microsomes show that cytochrome 2D6 and 1A2 lead to the formation of the _8-hydroxy metabolite_ of mirtazapine. The  CYP3A enzyme metabolizes this drug into its _N-desmethyl and N-oxide_ metabolites. There are various other unconjugated metabolites of this drug that are pharmacologically active, but are measured in the blood at limited concentrations.","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e19\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"265.35 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"**General effects and a note on suicidality**  Mirtazapine is effective in treating moderate to severe depression and treats many symptoms normally associated with this condition. These symptoms may include disturbed sleep, lack of appetite, and anhedonia, in addition to anxiety.. It is important to note that suicidal ideation and behavior may emerge or increase during treatment with mirtazapine, as with any other antidepressant. This risk is especially pronounced in younger individuals. Patients, medical professionals, and families should monitor for suicidal thoughts, worsening depression, anxiety, agitation, sleep changes, irritable behavior, aggression, impulsivity, restlessness, and other unusual behavior when this drug is taken or the dose is adjusted. Do not administer mirtazapine to children. When deciding to prescribe this drug, carefully consider the increased risk of suicidal thoughts and behavior, especially in young adults.  **Effects on appetite and weight gain**  In addition to the above effects, mirtazapine exerts stimulating effects on appetite, and has been used for increasing appetite and decreasing nausea in cancer patients.  Some studies and case reports have shown that this drug improves eating habits and weight gain in patients suffering from anorexia nervosa when administered in conjunction with psychotherapy and/or other psychotropic drugs. In a clinical trial, women with depression experienced a clinically significant mean increase in body weight, fat mass, and concentrations of leptin when treated with mirtazapine for a 6-week period, with a lack of effect on glucose homeostasis.  **Effects on sleep**  The use of mirtazapine to treat disordered sleep has been leveraged from its tendency to cause somnolence, which is a frequently experienced adverse effect by patients taking this drug. Mirtazapine has been shown to exert beneficial effects on sleep latency, duration, and quality due to its sedating properties. Insomnia is a common occurrence in patients with depression, and mirtazapine has been found to be efficacious in treating this condition.","Physical Description":"Solid","PubChemId":4205,"Record Description":["LiverTox|CNS|Antipsychotic|Atypical"],"Records":{"UNII":{"Impurities":["acyclomirtazapine alcohol","mirtazapine carboxylic acid","1-ketomirtazapine","mirtazapine n-oxide","desmethylmirtazapine","10-ketomirtazapine","4-methyl-1-(3-methyl-2-pyridinyl)-2-phenylpiperazine"]}},"RefChem":"55652","RefCount":4,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Mirtazapine","Name":"Mirtazapine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q421930","Name":"Mirtazapine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00370","Name":"Mirtazapine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/4205","Name":"Mirtazapine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=85650-52-8","Name":"Mirtazapine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014514","Name":"Mirtazapine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07570","Name":"Mirtazapine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/A051Q2099Q","Name":"Mirtazapine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0023325","Name":"Mirtazapine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 4205, Mirtazapine. Accessed January 2, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/4205\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/4205\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Mirtazapine. UNII: A051Q2099Q. Global Substance Registration System. Accessed January 2, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A051Q2099Q\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/A051Q2099Q\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed January 2, 2026. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4","SaltData":[{"AcidCount":1,"Amine":"Mirtazapine","AmineCount":2,"Formula":"O","Name":"hemihemihydrate","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 117.05 90.154\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h118v91H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m42.153 2.465 3.326 10.774M49.954 17.781l11.553 2.634M61.507 20.415l4.495 14.562M66.002 34.977l-7.471 8.055M52.332 45.397l-11.551-2.634M40.781 42.763l-4.496-14.562M43.756 20.146l-7.471 8.055M40.781 42.763l-11.915 9.502\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m28.866 52.265-13.203-7.628M26.428 53.673l-10.765-6.221\"/\u003e\u003c/g\u003e\u003cpath d=\"m15.663 44.637-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m2.465 52.257.005 15.248M4.904 53.664l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m2.47 67.505 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m15.673 75.133 13.198-7.62M15.673 72.318l10.759-6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m28.866 52.265.005 15.248M28.871 67.513l11.921 9.495M40.792 77.008l14.855-3.397\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.254 59.878-6.607 13.733M63.841 62.204l-5.386 11.195\"/\u003e\u003c/g\u003e\u003cpath d=\"m57.427 49.862 4.827 10.016M62.254 59.878l11.86-.893\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m86.041 71.322-6.129-8.982M83.233 71.534l-5.336-7.82\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m79.912 62.34 3.065 4.491M77.897 63.714l2.668 3.91\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m86.041 71.322-6.608 13.734\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m64.236 86.2 15.197-1.144M65.457 83.663l12.389-.933\"/\u003e\u003c/g\u003e\u003cpath d=\"M55.647 73.611 64.236 86.2\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M48.589 19.477h-.72l-2.62-4.066h-.029l.029.595q.024.357.024.732v2.739h-.565v-4.9h.714l2.608 4.054h.029l-.018-.327-.023-.476q-.006-.262-.006-.483v-2.768h.577zM57.579 48.6h-.72l-2.62-4.066h-.029l.029.596q.024.357.024.732V48.6h-.565v-4.899h.714l2.607 4.054h.03l-.018-.327q-.012-.221-.023-.477-.006-.262-.006-.482v-2.768h.577zM79.392 61.183h-.721l-2.619-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath fill=\"none\" d=\"M3.303 88.105H.56V.56h2.743m81.9 87.545h2.743V.56h-2.743\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M91.66 89.594h-1.943v-.3l.772-.778q.221-.222.371-.393.154-.175.233-.34.078-.168.078-.364 0-.243-.146-.368-.143-.129-.372-.129-.214 0-.378.075-.161.075-.329.208l-.193-.243q.172-.147.393-.247.225-.1.507-.1.411 0 .65.207.24.208.24.576 0 .228-.097.432-.093.2-.264.396-.168.197-.393.418l-.614.604v.018h1.485z\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m45.479 13.239-1.663-5.387M49.954 17.781l5.776 1.317M58.531 43.032l3.735-4.028M52.332 45.397l-5.776-1.317M43.756 20.146l-3.736 4.028M57.427 49.862l2.413 5.008M74.114 58.985l-5.93.446\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M116.49 44.365q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.245-.572-.245-1.334 0-.75.245-1.309.25-.566.756-.882.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.221.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.393.523-.393 1.452M108.905 46.818h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619zM111.41 48.307h-1.943v-.3l.771-.778q.222-.222.372-.393.153-.175.232-.34.078-.168.078-.364 0-.243-.146-.368-.143-.128-.371-.128-.215 0-.379.075-.161.075-.329.207l-.193-.243q.172-.147.393-.247.225-.1.508-.1.41 0 .65.207.239.208.239.576 0 .228-.097.432-.092.2-.264.396-.168.197-.393.418l-.614.604v.018h1.486z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Mirtazapine hemihemihydrate","UNII":"8Z5UNK8A61"},{"AcidCount":1,"Amine":"Mirtazapine","AmineCount":1,"Formula":"Br","Name":"hydrobromide","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 109.984 85.779\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h110v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.726.998 3.326 10.774M48.527 16.313l11.553 2.635M60.08 18.948l4.495 14.562M64.575 33.51l-7.471 8.055M50.906 43.93l-11.552-2.634M39.354 41.296l-4.496-14.562M42.329 18.679l-7.471 8.055M39.354 41.296l-11.915 9.502\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 50.798-13.203-7.629M25.002 52.205l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.236 43.169-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 50.789.005 15.249M3.477 52.197l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 66.038 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 73.666 13.198-7.62M14.247 70.85l10.758-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.439 50.798.005 15.248M27.444 66.046l11.921 9.495M39.365 75.541l14.855-3.398\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M60.827 58.411 54.22 72.143M62.414 60.737l-5.386 11.195\"/\u003e\u003c/g\u003e\u003cpath d=\"m56 48.394 4.827 10.017M60.827 58.411l11.86-.893\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m84.614 69.855-6.129-8.982M81.806 70.067l-5.335-7.82\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m78.485 60.873 3.064 4.491M76.471 62.247l2.667 3.91\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.614 69.855-6.608 13.733\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.809 84.732 15.197-1.144M64.03 82.195l12.389-.932\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.22 72.143 8.589 12.589\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.162 18.009h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565V13.11h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V13.11h.577zM56.152 47.133h-.72l-2.62-4.066h-.029l.029.595q.024.358.024.733v2.738h-.565v-4.899h.714l2.608 4.054h.029l-.018-.328-.023-.476q-.006-.262-.006-.482v-2.768h.577zM77.965 59.716h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.052 11.772-1.663-5.387M48.527 16.313l5.776 1.317M57.104 41.565l3.736-4.028M50.906 43.93l-5.776-1.317M42.329 18.679l-3.736 4.027M56 48.394l2.413 5.009M72.687 57.518l-5.93.447\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg fill=\"#a62929\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M104.306 40.44q.916 0 1.387.274.47.267.47.94 0 .435-.244.721-.238.285-.691.363v.035q.31.048.56.179t.393.375q.149.238.149.619 0 .667-.459 1.03-.458.363-1.244.363h-1.72V40.44zm.119 2.089q.631 0 .863-.202.238-.203.238-.601 0-.405-.286-.578-.286-.178-.911-.178h-.809v1.559zm-.905.512v1.774h.988q.655 0 .905-.25.256-.256.256-.666 0-.381-.268-.62-.262-.238-.941-.238zm5.475-1.446q.102 0 .221.012.125.006.208.029l-.071.554q-.09-.018-.197-.03-.107-.018-.202-.018-.28 0-.53.155-.244.155-.393.435-.149.274-.149.649v1.958h-.601v-3.673h.494l.065.667h.03q.179-.298.459-.518.279-.22.666-.22M102.345 45.339h-.619v-2.286h-2.512v2.286H98.6V40.44h.614v2.071h2.512V40.44h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Mirtazapine hydrobromide","UNII":"R24NHR59AG"},{"AcidCount":1,"Amine":"Mirtazapine","AmineCount":1,"Formula":"Cl","Name":"hydrochloride","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 108.569 85.779\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h109v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.726.998 3.326 10.774M48.527 16.313l11.553 2.635M60.08 18.948l4.495 14.562M64.575 33.51l-7.471 8.055M50.906 43.93l-11.552-2.634M39.354 41.296l-4.496-14.562M42.329 18.679l-7.471 8.055M39.354 41.296l-11.915 9.502\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 50.798-13.203-7.629M25.002 52.205l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.236 43.169-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 50.789.005 15.249M3.477 52.197l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 66.038 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 73.666 13.198-7.62M14.247 70.85l10.758-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.439 50.798.005 15.248M27.444 66.046l11.921 9.495M39.365 75.541l14.855-3.398\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M60.827 58.411 54.22 72.143M62.414 60.737l-5.386 11.195\"/\u003e\u003c/g\u003e\u003cpath d=\"m56 48.394 4.827 10.017M60.827 58.411l11.86-.893\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m84.614 69.855-6.129-8.982M81.806 70.067l-5.335-7.82\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m78.485 60.873 3.064 4.491M76.471 62.247l2.667 3.91\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.614 69.855-6.608 13.733\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.809 84.732 15.197-1.144M64.03 82.195l12.389-.932\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.22 72.143 8.589 12.589\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.162 18.009h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565V13.11h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V13.11h.577zM56.152 47.133h-.72l-2.62-4.066h-.029l.029.595q.024.358.024.733v2.738h-.565v-4.899h.714l2.608 4.054h.029l-.018-.328-.023-.476q-.006-.262-.006-.482v-2.768h.577zM77.965 59.716h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.052 11.772-1.663-5.387M48.527 16.313l5.776 1.317M57.104 41.565l3.736-4.028M50.906 43.93l-5.776-1.317M42.329 18.679l-3.736 4.027M56 48.394l2.413 5.009M72.687 57.518l-5.93.447\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg fill=\"#1ff01f\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M105.252 41.038q-.786 0-1.238.53-.453.524-.453 1.446 0 .911.417 1.447.423.53 1.268.53.322 0 .607-.054.292-.059.566-.143v.536q-.274.101-.566.149-.291.054-.696.054-.744 0-1.25-.31-.5-.309-.75-.875-.25-.572-.25-1.339 0-.745.267-1.31.274-.566.804-.881.53-.322 1.28-.322.78 0 1.351.286l-.244.524q-.226-.101-.506-.185-.274-.083-.607-.083m2.757 4.423h-.602v-5.215h.602zM102.345 45.461h-.619v-2.286h-2.512v2.286H98.6v-4.899h.614v2.071h2.512v-2.071h.619z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Mirtazapine hydrochloride","UNII":"42CIX4573G"}],"Salts":["hemihemihydrate","hydrobromide","hydrochloride"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S4 substance"},{"gov":"Brazil","ref":["3"],"schedule":"C1 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"},{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"},{"gov":"European Union","ref":[],"schedule":"prescription only substance"}],"Solubility":"slightly soluble in water","StereoisomerData":[],"StereoisomerType":"enantiomer","Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 85.66 85.779\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h86v86H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m40.726.998 3.326 10.774M48.527 16.313l11.553 2.635M60.08 18.948l4.495 14.562M64.575 33.51l-7.471 8.055M50.906 43.93l-11.552-2.634M39.354 41.296l-4.496-14.562M42.329 18.679l-7.471 8.055M39.354 41.296l-11.915 9.502\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.439 50.798-13.203-7.629M25.002 52.205l-10.766-6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.236 43.169-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 50.789.005 15.249M3.477 52.197l.004 12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.043 66.038 13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 73.666 13.198-7.62M14.247 70.85l10.758-6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m27.439 50.798.005 15.248M27.444 66.046l11.921 9.495M39.365 75.541l14.855-3.398\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M60.827 58.411 54.22 72.143M62.414 60.737l-5.386 11.195\"/\u003e\u003c/g\u003e\u003cpath d=\"m56 48.394 4.827 10.017M60.827 58.411l11.86-.893\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m84.614 69.855-6.129-8.982M81.806 70.067l-5.335-7.82\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m78.485 60.873 3.064 4.491M76.471 62.247l2.667 3.91\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m84.614 69.855-6.608 13.733\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m62.809 84.732 15.197-1.144M64.03 82.195l12.389-.932\"/\u003e\u003c/g\u003e\u003cpath d=\"m54.22 72.143 8.589 12.589\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M47.162 18.009h-.72l-2.619-4.066h-.03l.03.596q.023.357.023.732v2.738h-.565V13.11h.714l2.608 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482V13.11h.577zM56.152 47.133h-.72l-2.62-4.066h-.029l.029.595q.024.358.024.733v2.738h-.565v-4.899h.714l2.608 4.054h.029l-.018-.328-.023-.476q-.006-.262-.006-.482v-2.768h.577zM77.965 59.716h-.72l-2.62-4.066h-.03l.03.595q.024.357.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m44.052 11.772-1.663-5.387M48.527 16.313l5.776 1.317M57.104 41.565l3.736-4.028M50.906 43.93l-5.776-1.317M42.329 18.679l-3.736 4.027M56 48.394l2.413 5.009M72.687 57.518l-5.93.447\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Mirtazapine","Toxicity Data":"LD50: 600-720mg/kg (oral, mice) (L1855)\nLD50: 320-490mg/kg (oral, rat) (L1855)","Treatment":"Treatment should consist of those general measures employed in the management of overdose with any drug effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. There is no experience with the use of forced diuresis, dialysis, hemoperfusion or exchange transfusion in the treatment of mirtazapine overdosage. No specific antidotes for mirtazapine are known. (L1712)","UNII":"A051Q2099Q","Wikidata":"Q421930","Wikipedia":"Mirtazapine","XLogP":3.3}